{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:20:29Z","timestamp":1790328029162,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.vascn.2007.10.003","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T18:32:04Z","timestamp":1196879524000},"page":"114-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK\u2013PD experiments"],"prefix":"10.1016","volume":"57","author":[{"given":"Paulien G.M.","family":"Ravenstijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn","family":"Hameetman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hywel","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Mottart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"de Ville de Goyet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lemarchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"van Belle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.vascn.2007.10.003_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbr.2003.08.014","article-title":"The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-Dopa","volume":"151","author":"Alam","year":"2004","journal-title":"Behavioural Brain Research"},{"issue":"8","key":"10.1016\/j.vascn.2007.10.003_bib2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.44.8.1491","article-title":"Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP Parkinsonian monkeys","volume":"44","author":"Alexander","year":"1994","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.vascn.2007.10.003_bib3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.44.8.1491","article-title":"Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP Parkinsonian monkeys","volume":"44","author":"Alexander","year":"1994","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S1461145703004036","article-title":"Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone","volume":"7","author":"Antkiewicz-Michaluk","year":"2004","journal-title":"International Journal of Neuropsychopharmacology,"},{"issue":"4","key":"10.1016\/j.vascn.2007.10.003_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0940-2993(11)80259-9","article-title":"RITA-registry of industrial toxicology animal-data-guides for organ sampling and trimming procedures in rats","volume":"47","author":"Bahnemann","year":"1995","journal-title":"Experimental and Toxicologic Pathology"},{"issue":"5","key":"10.1016\/j.vascn.2007.10.003_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/35072550","article-title":"Experimental models of Parkinson's disease","volume":"2","author":"Beal","year":"2001","journal-title":"Nature Reviews. Neuroscience"},{"issue":"4","key":"10.1016\/j.vascn.2007.10.003_bib7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/bies.10067","article-title":"Animal models of Parkinson's disease","volume":"24","author":"Betarbet","year":"2002","journal-title":"Bioessays"},{"issue":"12","key":"10.1016\/j.vascn.2007.10.003_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nature Neuroscience"},{"issue":"7 Suppl 2","key":"10.1016\/j.vascn.2007.10.003_bib9","first-page":"S30","article-title":"New pharmacologic horizons in the treatment of Parkinson disease","volume":"67","author":"Bonuccelli","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.vascn.2007.10.003_bib10","series-title":"Pathology of the fisher rat\u2014reference and atlas","author":"Boorman","year":"1990"},{"issue":"16","key":"10.1016\/j.vascn.2007.10.003_bib11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: The multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1016\/j.vascn.2007.10.003_bib12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1460-9568.2005.04281.x","article-title":"6-Hydroxydopamine-induced alterations in blood-brain barrier permeability","volume":"22","author":"Carvey","year":"2005","journal-title":"European Journal of Neuroscience"},{"issue":"3\u20134","key":"10.1016\/j.vascn.2007.10.003_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10928-005-0039-x","article-title":"Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease","volume":"32","author":"Chan","year":"2005","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"5","key":"10.1016\/j.vascn.2007.10.003_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.mjt.0000174353.28012.a7","article-title":"Neuroprotective therapy in Parkinson disease","volume":"13","author":"Chen","year":"2006","journal-title":"American Journal of Therapeutics"},{"issue":"6","key":"10.1016\/j.vascn.2007.10.003_bib15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","article-title":"Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging","volume":"15","author":"Cicchetti","year":"2002","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.vascn.2007.10.003_bib16","series-title":"Robbins' pathologic basis of disease","first-page":"31","article-title":"Cellular pathology II: Adaptations, intracellular accumulations, and cell aging","author":"Cotran","year":"1999"},{"issue":"6","key":"10.1016\/j.vascn.2007.10.003_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: Mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.vascn.2007.10.003_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.pharmtox.43.100901.140204","article-title":"The role of drug transporters at the blood-brain barrier","volume":"43","author":"de Boer","year":"2003","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"1","key":"10.1016\/j.vascn.2007.10.003_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-0173(97)00014-3","article-title":"Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier","volume":"25","author":"de Lange","year":"1997","journal-title":"Brain Research Brain Research Reviews"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0928-0987(00)00149-4","article-title":"In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin","volume":"12","author":"de Lange","year":"2000","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.expneurol.2004.01.023","article-title":"Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone","volume":"187","author":"Fleming","year":"2004","journal-title":"Experimental Neurology"},{"issue":"9","key":"10.1016\/j.vascn.2007.10.003_bib22","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1073\/pnas.0409713102","article-title":"Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein","volume":"102","author":"Fornai","year":"2005","journal-title":"Proceedings of the National Academy of Sciences, United States of America"},{"issue":"1","key":"10.1016\/j.vascn.2007.10.003_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nature Reviews.Cancer"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1023\/A:1012080106490","article-title":"Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method","volume":"14","author":"Hammarlund-Udenaes","year":"1997","journal-title":"Pharmaceutical Research"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0009-9236(98)90152-7","article-title":"Concentration\u2013response relationship of levodopa in patients at different stages of Parkinson's disease","volume":"64","author":"Harder","year":"1998","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2007.10.003_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1471-4159.2003.01533.x","article-title":"Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats","volume":"84","author":"Hoglinger","year":"2003","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.vascn.2007.10.003_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.20369","article-title":"Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo","volume":"57","author":"Kortekaas","year":"2005","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/j.vascn.2007.10.003_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1096\/fj.03-0677fje","article-title":"Rotenone induces non-specific central nervous system and systemic toxicity","volume":"18","author":"Lapointe","year":"2004","journal-title":"FASEB Journal"},{"issue":"1","key":"10.1016\/j.vascn.2007.10.003_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"Loscher","year":"2005","journal-title":"NeuroRx."},{"issue":"7","key":"10.1016\/j.vascn.2007.10.003_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of l-Dopa: Why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1471-4159.1989.tb07383.x","article-title":"Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine","volume":"53","author":"Moghaddam","year":"1989","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.049445","article-title":"LY503430, a novel {alpha}-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease","volume":"306","author":"Murray","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2003.12.023","article-title":"Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease","volume":"486","author":"O'Neill","year":"2004","journal-title":"European Jouranl of Pharmacology"},{"key":"10.1016\/j.vascn.2007.10.003_bib34","series-title":"Pathology of domestic animals:","first-page":"1","article-title":"Bones and Joints","author":"Palmer","year":"1993"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-0270(85)90026-3","article-title":"Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight","volume":"13","author":"Paxinos","year":"1985","journal-title":"Journal of Neuroscience Methods"},{"issue":"4","key":"10.1016\/j.vascn.2007.10.003_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.parkreldis.2005.12.002","article-title":"Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging","volume":"12","author":"Phinney","year":"2006","journal-title":"Parkinsonism Related Disorder"},{"issue":"5","key":"10.1016\/j.vascn.2007.10.003_bib37","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle","volume":"11","author":"Rosenblad","year":"1999","journal-title":"European Journal of Neuroscience"},{"issue":"1","key":"10.1016\/j.vascn.2007.10.003_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-2952(75)90304-4","article-title":"Mechanisms of action of 6-hydroxydopamine","volume":"24","author":"Sachs","year":"1975","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.brainres.2005.04.051","article-title":"Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease","volume":"1049","author":"Saravanan","year":"2005","journal-title":"Brain Research"},{"issue":"2","key":"10.1016\/j.vascn.2007.10.003_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0306-4522(94)90605-X","article-title":"Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat","volume":"59","author":"Sauer","year":"1994","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.vascn.2007.10.003_bib41","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1172\/JCI29178","article-title":"Diagnosis and treatment of Parkinson disease: Molecules to medicine","volume":"116","author":"Savitt","year":"2006","journal-title":"Journal of Clinical Investigation"},{"issue":"2\u20133","key":"10.1016\/j.vascn.2007.10.003_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-Glycoprotein, a gatekeeper in the blood\u2013brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"11","key":"10.1016\/j.vascn.2007.10.003_bib43","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.vascn.2007.10.003_bib44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell and Tissue Research"},{"issue":"1","key":"10.1016\/j.vascn.2007.10.003_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/exnr.2002.8072","article-title":"Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation","volume":"179","author":"Sherer","year":"2003","journal-title":"Experimental Neurology"},{"issue":"1\u20132","key":"10.1016\/j.vascn.2007.10.003_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2005.05.051","article-title":"Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion","volume":"1051","author":"Sindhu","year":"2005","journal-title":"Brain Research"},{"issue":"9\u201310","key":"10.1016\/j.vascn.2007.10.003_bib47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1089\/ars.2005.7.1110","article-title":"Protective effect of melatonin on rotenone plus Ca2+-induced mitochondrial oxidative stress and PC12 cell death","volume":"7","author":"Sousa","year":"2005","journal-title":"Antioxidants and Redox Signalling"},{"issue":"1\u20133","key":"10.1016\/j.vascn.2007.10.003_bib48","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(03)00421-6","article-title":"Ca2+-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone","volume":"543","author":"Sousa","year":"2003","journal-title":"FEBS Letters"},{"key":"10.1016\/j.vascn.2007.10.003_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00441-004-0937-z","article-title":"Neurotoxicant-induced animal models of Parkinson's disease: Understanding the role of rotenone, maneb and paraquat in neurodegeneration","volume":"318","author":"Uversky","year":"2004","journal-title":"Cell and Tissue Research"},{"issue":"1","key":"10.1016\/j.vascn.2007.10.003_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0928-0987(01)00150-6","article-title":"Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier","volume":"14","author":"van der Sandt","year":"2001","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"2\u20133","key":"10.1016\/j.vascn.2007.10.003_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejps.2005.09.009","article-title":"Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse","volume":"27","author":"Vautier","year":"2006","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"3","key":"10.1016\/j.vascn.2007.10.003_bib53","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.neuropharm.2006.04.015","article-title":"Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle","volume":"51","author":"Visanji","year":"2006","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2007.10.003_bib52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/cne.20305","article-title":"Variable effects of chronic subcutaneous administration of rotenone on striatal histology","volume":"478","author":"Zhu","year":"2004","journal-title":"Journal of Comparative Neurology"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871907002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871907002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T23:52:57Z","timestamp":1761004377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871907002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S1056871907002626"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2007.10.003","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK\u2013PD experiments","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2007.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}